$XLRN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ACCELERON PHARMA INC. Get notifications about new insider transactions in ACCELERON PHARMA INC for free.
Page: < prev 1 ... 2 3 4 5 6 7 8 9 ... 11 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 20 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 5.08 | 24,090 | 122,377 | 160,674 | 136.6 K to 160.7 K (+17.64 %) |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Option Exercise | A | 27.97 | 10,000 | 279,700 | 10,000 | |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Option Exercise | A | 27.97 | 10,000 | 279,700 | 10,000 | |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Option Exercise | A | 27.97 | 10,000 | 279,700 | 10,000 | |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Option Exercise | A | 27.97 | 10,000 | 279,700 | 10,000 | |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Option Exercise | A | 27.97 | 10,000 | 279,700 | 10,000 | |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Option Exercise | A | 27.97 | 10,000 | 279,700 | 10,000 | |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Option Exercise | A | 27.97 | 10,000 | 279,700 | 10,000 | |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | A | 27.97 | 36,400 | 1,018,108 | 36,400 | |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Grant | A | 0.00 | 6,000 | 0 | 84,751 | 78.8 K to 84.8 K (+7.62 %) |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | A | 27.97 | 30,800 | 861,476 | 30,800 | |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Grant | A | 0.00 | 5,100 | 0 | 81,223 | 76.1 K to 81.2 K (+6.70 %) |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | A | 27.97 | 36,000 | 1,006,920 | 36,000 | |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Grant | A | 0.00 | 6,000 | 0 | 97,604 | 91.6 K to 97.6 K (+6.55 %) |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | A | 27.97 | 45,000 | 1,258,650 | 45,000 | |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Grant | A | 0.00 | 7,500 | 0 | 127,156 | 119.7 K to 127.2 K (+6.27 %) |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | A | 27.97 | 30,800 | 861,476 | 30,800 | |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Grant | A | 0.00 | 5,100 | 0 | 92,600 | 87.5 K to 92.6 K (+5.83 %) |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | A | 27.97 | 105,000 | 2,936,850 | 105,000 | |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Grant | A | 0.00 | 17,500 | 0 | 136,584 | 119.1 K to 136.6 K (+14.70 %) |
| Feb 29 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 3.88 | 8,000 | 31,040 | 5,515 | |
| Feb 29 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 3.88 | 8,000 | 31,040 | 78,751 | 70.8 K to 78.8 K (+11.31 %) |
| Apr 08 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 3.88 | 13,484 | 52,318 | 10,209 | |
| Apr 08 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 5.08 | 2,344 | 11,908 | 0 | |
| Apr 08 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 7.12 | 12,500 | 89,000 | 12,500 | |
| Apr 08 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 5.28 | 3,942 | 20,814 | 28,365 | |
| Apr 08 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 32.00 | 32,270 | 1,032,640 | 127,156 | 159.4 K to 127.2 K (-20.24 %) |
| Apr 08 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 3.88 | 13,484 | 52,318 | 159,426 | 145.9 K to 159.4 K (+9.24 %) |
| Apr 08 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 5.08 | 2,344 | 11,908 | 145,942 | 143.6 K to 145.9 K (+1.63 %) |
| Apr 08 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 7.12 | 12,500 | 89,000 | 143,598 | 131.1 K to 143.6 K (+9.53 %) |
| Apr 08 2016 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 5.28 | 3,942 | 20,814 | 131,098 | 127.2 K to 131.1 K (+3.10 %) |
| Apr 08 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 5.08 | 14,000 | 71,120 | 5,896 | |
| Apr 08 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 32.00 | 23,920 | 765,440 | 85,604 | 109.5 K to 85.6 K (-21.84 %) |
| Apr 08 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 5.08 | 14,000 | 71,120 | 109,524 | 95.5 K to 109.5 K (+14.66 %) |
| Apr 08 2016 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 32.00 | 2,080 | 66,560 | 95,524 | 97.6 K to 95.5 K (-2.13 %) |
| Jan 11 2016 | XLRN | ACCELERON PHARMA I ... | CELGENE CORP /DE/ | 10% Owner | Buy | P | 40.00 | 800,000 | 32,000,000 | 5,372,887 | 4.6 M to 5.4 M (+17.49 %) |
| Dec 23 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 7,500 | 29,100 | 21,251 | |
| Dec 23 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 7,500 | 29,100 | 87,500 | 80 K to 87.5 K (+9.38 %) |
| Oct 21 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.28 | 5,516 | 29,124 | 10,984 | |
| Oct 21 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.08 | 6,250 | 31,750 | 0 | |
| Oct 21 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 1.80 | 2,300 | 4,140 | 0 | |
| Oct 21 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.28 | 5,516 | 29,124 | 70,751 | 65.2 K to 70.8 K (+8.46 %) |
| Oct 21 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.08 | 6,250 | 31,750 | 65,235 | 59 K to 65.2 K (+10.60 %) |
| Oct 21 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 1.80 | 2,300 | 4,140 | 58,985 | 56.7 K to 59 K (+4.06 %) |
| Oct 16 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 23.94 | 500 | 11,970 | 8,500 | 9 K to 8.5 K (-5.56 %) |
| Oct 16 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 22.69 | 700 | 15,883 | 9,000 | 9.7 K to 9 K (-7.22 %) |
| Oct 16 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 23.93 | 2,400 | 57,432 | 91,604 | 94 K to 91.6 K (-2.55 %) |
| Oct 16 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 22.66 | 2,400 | 54,384 | 94,004 | 96.4 K to 94 K (-2.49 %) |
| Oct 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 7,000 | 27,160 | 28,751 | |
| Oct 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 24.64 | 3,460 | 85,254 | 80,000 | 83.5 K to 80 K (-4.15 %) |
| Oct 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 24.12 | 3,540 | 85,385 | 83,460 | 87 K to 83.5 K (-4.07 %) |
| Oct 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 7,000 | 27,160 | 87,000 | 80 K to 87 K (+8.75 %) |
| Oct 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 5.08 | 19,000 | 96,520 | 202,133 | |
| Oct 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 24.58 | 12,452 | 306,070 | 119,084 | 131.5 K to 119.1 K (-9.47 %) |
| Oct 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 24.01 | 6,548 | 157,217 | 131,536 | 138.1 K to 131.5 K (-4.74 %) |
| Oct 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 5.08 | 19,000 | 96,520 | 138,084 | 119.1 K to 138.1 K (+15.96 %) |
| Sep 18 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 34.96 | 400 | 13,984 | 9,700 | 10.1 K to 9.7 K (-3.96 %) |
| Sep 18 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 34.93 | 200 | 6,986 | 96,404 | 96.6 K to 96.4 K (-0.21 %) |
| Sep 18 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 33.55 | 300 | 10,065 | 96,604 | 96.9 K to 96.6 K (-0.31 %) |
| Sep 18 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 32.22 | 1,100 | 35,442 | 96,904 | 98 K to 96.9 K (-1.12 %) |
| Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 5.28 | 2,000 | 10,560 | 32,307 | |
| Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 33.61 | 2,000 | 67,220 | 119,656 | 121.7 K to 119.7 K (-1.64 %) |
| Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 5.28 | 2,000 | 10,560 | 121,656 | 119.7 K to 121.7 K (+1.67 %) |
| Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 3.88 | 11,485 | 44,562 | 13,515 | |
| Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 35.00 | 33,000 | 1,155,000 | 56,685 | 89.7 K to 56.7 K (-36.80 %) |
| Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 3.88 | 11,485 | 44,562 | 89,685 | 78.2 K to 89.7 K (+14.69 %) |
| Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 3.88 | 5,500 | 21,340 | 22,000 | |
| Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 34.17 | 1,400 | 47,838 | 76,123 | 77.5 K to 76.1 K (-1.81 %) |
| Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 33.07 | 4,100 | 135,587 | 77,523 | 81.6 K to 77.5 K (-5.02 %) |
| Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 3.88 | 5,500 | 21,340 | 81,623 | 76.1 K to 81.6 K (+7.23 %) |
| Sep 15 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 0.40 | 8,500 | 3,400 | 0 | |
| Sep 15 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 0.40 | 8,500 | 3,400 | 119,084 | 110.6 K to 119.1 K (+7.69 %) |
| Sep 11 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Grant | A | 0.00 | 40,000 | 0 | 78,200 | 38.2 K to 78.2 K (+104.71 %) |
| Sep 11 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Grant | A | 0.00 | 40,000 | 0 | 76,123 | 36.1 K to 76.1 K (+110.73 %) |
| Sep 11 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Grant | A | 0.00 | 46,000 | 0 | 98,004 | 52 K to 98 K (+88.45 %) |
| Sep 11 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Grant | A | 0.00 | 62,000 | 0 | 119,656 | 57.7 K to 119.7 K (+107.53 %) |
| Sep 11 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Grant | A | 0.00 | 40,000 | 0 | 80,000 | 40 K to 80 K (+100.00 %) |
| Sep 11 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Grant | A | 0.00 | 89,000 | 0 | 110,584 | 21.6 K to 110.6 K (+412.34 %) |
| Sep 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 1,500 | 5,820 | 35,751 | |
| Sep 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 5,000 | 19,400 | 37,251 | |
| Sep 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 31.16 | 176 | 5,484 | 40,000 | 40.2 K to 40 K (-0.44 %) |
| Sep 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 30.45 | 724 | 22,046 | 40,176 | 40.9 K to 40.2 K (-1.77 %) |
| Sep 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 29.39 | 600 | 17,634 | 40,900 | 41.5 K to 40.9 K (-1.45 %) |
| Sep 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 1,500 | 5,820 | 41,500 | 40 K to 41.5 K (+3.75 %) |
| Sep 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 31.07 | 1,293 | 40,174 | 40,000 | 41.3 K to 40 K (-3.13 %) |
| Sep 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 30.22 | 2,500 | 75,550 | 41,293 | 43.8 K to 41.3 K (-5.71 %) |
| Sep 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 29.11 | 1,207 | 35,136 | 43,793 | 45 K to 43.8 K (-2.68 %) |
| Sep 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 5,000 | 19,400 | 45,000 | 40 K to 45 K (+12.50 %) |
| Sep 10 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 5.08 | 19,000 | 96,520 | 221,133 | |
| Sep 10 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 31.06 | 5,173 | 160,673 | 21,584 | 26.8 K to 21.6 K (-19.33 %) |
| Sep 10 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 30.27 | 9,028 | 273,278 | 26,757 | 35.8 K to 26.8 K (-25.23 %) |
| Sep 10 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 29.16 | 4,799 | 139,939 | 35,785 | 40.6 K to 35.8 K (-11.82 %) |
| Sep 10 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 5.08 | 19,000 | 96,520 | 40,584 | 21.6 K to 40.6 K (+88.03 %) |
| Aug 25 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 3.88 | 20,000 | 77,600 | 3,500 | |
| Aug 25 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 3.88 | 20,000 | 77,600 | 52,004 | 32 K to 52 K (+62.49 %) |
| Aug 19 2015 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Sell | S | 30.25 | 407,259 | 12,319,585 | 1,303,232 | 1.7 M to 1.3 M (-23.81 %) |
| Aug 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 5.08 | 1,600 | 8,128 | 19,896 | |
| Aug 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 0.48 | 4,000 | 1,920 | 0 | |
| Aug 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 31.69 | 200 | 6,338 | 10,100 | 10.3 K to 10.1 K (-1.94 %) |
| Aug 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 30.99 | 800 | 24,792 | 10,300 | 11.1 K to 10.3 K (-7.21 %) |
| Aug 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 31.95 | 400 | 12,780 | 11,100 | 11.5 K to 11.1 K (-3.48 %) |
| Aug 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 31.69 | 200 | 6,338 | 32,004 | 32.2 K to 32 K (-0.62 %) |
| Aug 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 31.00 | 1,400 | 43,400 | 32,204 | 33.6 K to 32.2 K (-4.17 %) |
| Aug 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 5.08 | 1,600 | 8,128 | 33,604 | 32 K to 33.6 K (+5.00 %) |
| Aug 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 31.60 | 1,210 | 38,236 | 32,004 | 33.2 K to 32 K (-3.64 %) |
| Aug 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 30.83 | 2,790 | 86,016 | 33,214 | 36 K to 33.2 K (-7.75 %) |
| Aug 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 0.48 | 4,000 | 1,920 | 36,004 | 32 K to 36 K (+12.50 %) |
| Aug 19 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 5.28 | 2,000 | 10,560 | 34,307 | |
| Aug 19 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 30.46 | 2,000 | 60,920 | 57,656 | 59.7 K to 57.7 K (-3.35 %) |
| Aug 19 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 5.28 | 2,000 | 10,560 | 59,656 | 57.7 K to 59.7 K (+3.47 %) |
| Aug 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 3.88 | 1,039 | 4,031 | 27,500 | |
| Aug 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 4,461 | 26,231 | 0 | |
| Aug 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 31.74 | 2,200 | 69,828 | 36,123 | 38.3 K to 36.1 K (-5.74 %) |
| Aug 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 30.22 | 3,300 | 99,726 | 38,323 | 41.6 K to 38.3 K (-7.93 %) |
| Aug 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 3.88 | 1,039 | 4,031 | 41,623 | 40.6 K to 41.6 K (+2.56 %) |
| Aug 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 4,461 | 26,231 | 40,584 | 36.1 K to 40.6 K (+12.35 %) |
| Aug 12 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 1,500 | 5,820 | 42,251 | |
| Aug 12 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 5,000 | 19,400 | 43,751 | |
| Aug 12 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 28.54 | 1,500 | 42,810 | 40,000 | 41.5 K to 40 K (-3.61 %) |
| Aug 12 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 1,500 | 5,820 | 41,500 | 40 K to 41.5 K (+3.75 %) |
| Aug 12 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 29.23 | 100 | 2,923 | 40,000 | 40.1 K to 40 K (-0.25 %) |
| Aug 12 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 28.51 | 4,900 | 139,699 | 40,100 | 45 K to 40.1 K (-10.89 %) |
| Aug 12 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 5,000 | 19,400 | 45,000 | 40 K to 45 K (+12.50 %) |
| Aug 12 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 5.08 | 19,000 | 96,520 | 240,133 | |
| Aug 12 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 29.22 | 500 | 14,610 | 21,584 | 22.1 K to 21.6 K (-2.26 %) |
| Aug 12 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 28.51 | 18,500 | 527,435 | 22,084 | 40.6 K to 22.1 K (-45.58 %) |
| Aug 12 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 5.08 | 19,000 | 96,520 | 40,584 | 21.6 K to 40.6 K (+88.03 %) |
| Aug 03 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 0.40 | 4,000 | 1,600 | 8,500 | |
| Aug 03 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 0.40 | 4,000 | 1,600 | 21,584 | 17.6 K to 21.6 K (+22.75 %) |
| Aug 03 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 5,895 | 31,126 | 6,250 | |
| Aug 03 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 7,527 | 39,743 | 2,346 | |
| Aug 03 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.28 | 5,895 | 31,126 | 36,123 | 30.2 K to 36.1 K (+19.50 %) |
| Aug 03 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.28 | 7,527 | 39,743 | 30,228 | 22.7 K to 30.2 K (+33.16 %) |
| Jul 30 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 5,000 | 19,400 | 48,751 | |
| Jul 30 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 5,000 | 19,400 | 40,000 | 35 K to 40 K (+14.29 %) |
| Jul 21 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 5.08 | 800 | 4,064 | 21,496 | |
| Jul 21 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 0.48 | 4,000 | 1,920 | 4,000 | |
| Jul 21 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 33.22 | 200 | 6,644 | 11,500 | 11.7 K to 11.5 K (-1.71 %) |
| Jul 21 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 32.31 | 1,000 | 32,310 | 11,700 | 12.7 K to 11.7 K (-7.87 %) |
| Jul 21 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 33.22 | 800 | 26,576 | 32,004 | 32.8 K to 32 K (-2.44 %) |
| Jul 21 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 5.08 | 800 | 4,064 | 32,804 | 32 K to 32.8 K (+2.50 %) |
| Jul 21 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 32.74 | 100 | 3,274 | 32,004 | 32.1 K to 32 K (-0.31 %) |
| Jul 21 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 32.29 | 3,900 | 125,931 | 32,104 | 36 K to 32.1 K (-10.83 %) |
| Jul 21 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 0.48 | 4,000 | 1,920 | 36,004 | 32 K to 36 K (+12.50 %) |
| Jul 17 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 5.28 | 1,193 | 6,299 | 36,307 | |
| Jul 17 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 3.88 | 807 | 3,131 | 23,693 | |
| Jul 17 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 31.38 | 2,000 | 62,760 | 57,656 | 59.7 K to 57.7 K (-3.35 %) |
| Jul 17 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 5.28 | 1,193 | 6,299 | 59,656 | 58.5 K to 59.7 K (+2.04 %) |
| Jul 17 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 3.88 | 807 | 3,131 | 58,463 | 57.7 K to 58.5 K (+1.40 %) |
| Jul 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 5,500 | 32,340 | 4,461 |